Hot Stocks With Major News: CYTK, CBMX, CAMT, EXAS
Cytokinetics, Inc. (NASDAQ:CYTK) rose 21.92% to $1.78 on volume of 8.68M shares versus average-daily volume of 1.29M shares. Cytokinetics Inc. sent signals that its experimental drug for acute heart failures will have success in a mid-stage trail. Recently, the company and partner Amgen Inc. said they’d expanded their co-development deal for the drug, omecamtiv mecarbil, into Japan. The news suggested Amgen was confident in the drug advancing into a late-stage trial needed for approval, Cowen said. Cytokinetics, then said early Tuesday that study data would be presented at a September medical meeting. The company won’t release data before then, but investors interpreted the announcement as positive because companies don’t advertise presentations of failed studies.
How Should Investors Trade CYTK Now? Find Out Here
CombiMatrix Corp. (NASDAQ:CBMX) said its volumes of prenatal testing have shown a significant uptick since data from two National Institutes of Health studies showed the value of chromosomal microarray analysis. CombiMatrix Corporation shares gained 25.20% to $3.18. CBMX’s RSI is currently at 20.96 which indicates that the stock is oversold. CBMX is -82.04% below its 52-week high and 81.43% above its 52-week low. CombiMatrix Corporation is a molecular diagnostics company that operates primarily in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc.
What Should Investors Do With CBMX Now? Find Out Here
Camtek Ltd. (NASDAQ:CAMT) said it has entered into a frame engagement for ten semiconductor inspection systems with an Asian outsourced semiconductor assembly and test company. The first systems’ order, in excess of $2 million, will be installed during the second and third quarters, with expectations for additional systems’ orders over the next few quarters. Camtek Ltd. (Camtek) designs, develops, manufactures and markets automated solutions dedicated for enhancing production processes and yield for the semiconductor manufacturing and packaging and the printed circuit board (PCB) and integrated circuit (IC) substrate industries.
Is CAMT A Buy Or Sell At These Levels? Find Out Here
Exact Sciences Corp. (NASDAQ:EXAS), a Madison company developing a DNA-based, non-invasive test for colon cancer, said Tuesday it is trying to raise nearly $64 million in a stock offering. Exact will sell 5.5 million shares at a price of $12.35 in an offering that will close on Friday, the company said. The company said it will use the money for product development, to continue its efforts to obtain FDA approval of its cancer screening product, and for other general purposes. Exact in June submitted its application to federal regulators for approval to market the test, called Cologuard. The company released preliminary results of a large study of the product in April. The study showed that Cologuard detected 92% of patient cancers but just 42% of all precancerous polyps, below the company’s target of 50%.
Is EXAS a Solid Investment at These Levels? Find Out Here
Neither pennystockparlay.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Adviser or broker dealer in any jurisdiction whatsoever and none of the information provided by pennystockparlay.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. pennystockparlay.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through pennystockparlay.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
- Stock’s Buzzers – Hopto Inc (OTCBB:HPTO), Decision Diagnostics Corp (OTCBB:DECN), Plandai Biotechnology Inc (OTCMKTS:PLPL), MTN Group Ltd (ADR) (OTCMKTS:MTNOY)
- Stocks on the Move – ASTELLAS PHARMA INC (OTCMKTS:ALPMY), Max Sound Corp (OTCBB:MAXD), NanoTech Entertainment, Inc. (OTCMKTS:NTEK), New Energy Technologies Inc (OTCMKTS:NENE)
- Trending Stocks – Lenovo Group Limited (ADR) (OTCMKTS:LNCGY), Liquidmetal Technologies Inc (OTCBB:LQMT),Advanced Cell Technology, Inc. (OTCMKTS:ACTC), Indo Global Exchange(s) PteLtd (OTCMKTS:IGEX)
- Stocks in the News – Senesco Technologies, Inc. (OTCBB:SNTI), Accelerize New Media Inc (OTCBB:ACLZ), Telecom Corp of New Zealand (ADR) (OTCMKTS:NZTCY), A.P. Pharma, Inc. (OTCBB:APPA)
- Stock’s Trend Analysis Report – LIGHTSTREAM RES (OTCMKTS:LSTMF), Itochu Corp (ADR) (OTCMKTS:ITOCY), diaDexus, Inc. (OTCMKTS:DDXS), Imageware Systems Inc (OTCMKTS:IWSY)